Cargando…
Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
Guidelines on immunoprophylaxis for prevention of RSV infection recommend it in preterm babies born before 29 wGA; in babies affected by bronchopulmonary dysplasia or congenital heart defects; and in post-heart transplantation patients. On the contrary, immunoprophylaxis is not recommended in preter...
Autores principales: | Zuccotti, Gianvincenzo, Fabiano, Valentina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347811/ https://www.ncbi.nlm.nih.gov/pubmed/28257653 http://dx.doi.org/10.1186/s13052-017-0341-4 |
Ejemplares similares
-
RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020
por: Packnett, Elizabeth R., et al.
Publicado: (2022) -
Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration
por: Packnett, Elizabeth R., et al.
Publicado: (2023) -
Immunoprophylaxis of respiratory syncytial virus: global experience
por: Simoes, Eric AF
Publicado: (2002) -
Patient equity and respiratory syncytial virus Immunoprophylaxis
por: Cody Meissner, H.
Publicado: (2019) -
Seasonality in Respiratory Syncytial Virus Hospitalizations and Immunoprophylaxis
por: Kusma, Jennifer D., et al.
Publicado: (2023)